Neurogene Inc.
NGNE
$16.80
-$0.98-5.51%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -20.22M | -18.49M | -16.92M | 2.38M | -14.58M |
| Total Depreciation and Amortization | 807.00K | 817.00K | 825.00K | 828.00K | 828.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.28M | 2.66M | 1.20M | -15.93M | 554.00K |
| Change in Net Operating Assets | 2.56M | -879.00K | -6.75M | -4.25M | 1.63M |
| Cash from Operations | -15.56M | -15.89M | -21.65M | -16.97M | -11.57M |
| Capital Expenditure | -167.00K | -460.00K | -65.00K | -128.00K | -82.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 20.96M | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -28.80M | -23.15M | 30.00M | 5.00M | -- |
| Cash from Investing | -28.97M | -23.61M | 29.94M | 25.83M | -82.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -12.00K | -16.00K | -11.00K | -8.00K | -10.00K |
| Issuance of Common Stock | 143.00K | 415.00K | 629.00K | 1.00K | 35.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -7.14M | 94.30M | -1.86M |
| Cash from Financing | 131.00K | 399.00K | -6.52M | 94.30M | -1.84M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -44.40M | -39.11M | 1.76M | 103.16M | -13.49M |
